QuidelOrtho completed its acquisition of Lex Diagnostics for about $100 million in cash, bringing forward a CLIA-cleared Velo point-of-care molecular diagnostic system. The closing was triggered after FDA cleared both the Velo platform with an assay covering influenza A, influenza B, and COVID-19. QuidelOrtho said it expects to commercially launch Velo in the U.S. this year. At the same time, Danaher moved into another acquisition pathway by raising via senior notes and using proceeds in part to fund its planned $9.9 billion acquisition of Masimo patient monitoring technology. That type of large-scale medtech consolidation can affect adjacent diagnostics and clinical technology procurement cycles. Finally, Biocenture reported ongoing momentum in biopharma deal value tied to China partnerships, with Q1 2026 deal value reaching $79.22 billion and increasing about 17% from the prior year. The figures underline how cross-border partnering continues to supply capital and pipeline access for companies pursuing clinical expansion.